🔗 Permalink

Inventor profile of:

Mark Manning

City:

Johnstown, Colorado

Country:

United States

Published Applications:

Last publication date:

2024-09-19

Top Assignees for applications by Mark Manning

The entities that hold a legal rights for patent applications filed by inventor Manning Mark:

Coherus Biosciences, Inc. 68 Redwood City, CA United States
Acadia Pharmaceuticals, Inc. 1 San Diego, CA United States
Coherus Biosciences, Inc. 1 Redwood, CA United States

Recent patent applications by Manning Mark

Mark Manning from Johnstown, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-09-19

US20240309104A1

Chemistry; metallurgy

COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF

#2 | 2024-03-21

US20240091302A1

Human necessities

CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING SAME

#3 | 2023-02-21

US15337845

Human necessities

Stable protein compositions and methods of their use

#4 | 2022-02-10

US20220040300A1

Human necessities

Method of filling a container with no headspace

#5 | 2022-01-25

US15337519

Human necessities

High concentration formulations of adalimumab

#6 | 2021-10-21

US20210322549A1

Human necessities

Stable Aqueous Formulations of Natalizumab

#7 | 2021-01-14

US20210007991A1

Human necessities

ETANERCEPT FORMULATIONS EXHIBITING MARKED REDUCTION IN SUB-VISIBLE PARTICLES

#8 | 2020-12-31

US20200405865A1

Human necessities

ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL

#9 | 2019-11-14

US20190343955A1

Human necessities

Etanercept formulations stabilized with sodium chloride

#10 | 2019-11-07

US20190336601A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#11 | 2019-10-31

US20190328875A1

Human necessities

ETANERCEPT FORMULATIONS STABILIZED WITH MEGLUMINE

#12 | 2019-10-17

US20190314500A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#13 | 2019-10-17

US20190314499A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#14 | 2019-10-17

US20190314498A1

Human necessities

Etanercept Formulations Stabilized with Sodium Chloride

#15 | 2019-10-03

US20190298837A1

Human necessities

Method of reducing formation of etanercept aggregates or fragments

#16 | 2019-09-26

US20190290768A1

Human necessities

Stable aqueous etanercept composition

#17 | 2019-09-26

US20190290767A1

Human necessities

Method of reducing formation of etanercept aggregates or fragments

#18 | 2019-09-26

US20190290766A1

Human necessities

Stable aqueous etanercept composition

#19 | 2019-09-26

US20190290765A1

Human necessities

Method of Reducing Formation of Etanercept Aggregates or Fragments

#20 | 2019-07-18

US20190216930A1

Human necessities

Etanercept formulations stabilized with amino acids

#21 | 2019-06-20

US20190184017A1

Human necessities

Etanercept formulations stabilized with xylitol

#22 | 2019-03-07

US20190070294A1

Human necessities

Stable aqueous formulations of adalimumab

#23 | 2019-03-07

US20190070293A1

Human necessities

Stable aqueous formulations of adalimumab

#24 | 2019-03-07

US20190070292A1

Human necessities

Stable aqueous formulations of adalimumab

#25 | 2019-02-28

US20190060455A1

Human necessities

Stable aqueous formulations of adalimumab

#26 | 2018-11-01

US20180311352A1

Human necessities

Stable aqueous formulations of adalimumab

#27 | 2018-11-01

US20180311351A1

Human necessities

Stable aqueous formulations of adalimumab

#28 | 2018-11-01

US20180311350A1

Human necessities

Stable aqueous formulations of adalimumab

#29 | 2018-11-01

US20180311349A1

Human necessities

Stable aqueous formulations of adalimumab

#30 | 2018-07-12

US20180193463A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#31 | 2018-05-24

US20180140701A1

Human necessities

Stable aqueous formulations of adalimumab

#32 | 2018-05-10

US20180125982A1

Human necessities

Etanercept formulations stabilized with metal ions

#33 | 2018-03-01

US20180055930A1

Human necessities

Stable aqueous formulations of adalimumab

#34 | 2018-03-01

US20180055929A1

Human necessities

Stable aqueous formulations of adalimumab

#35 | 2018-02-15

US20180043020A1

Human necessities

METHOD OF REDUCING IMMUNOGENICITY OF DRUG PRODUCTS

#36 | 2018-02-15

US20180043019A1

Human necessities

Stable aqueous formulations of adalimumab

#37 | 2018-02-15

US20180043018A1

Human necessities

Stable aqueous formulations of adalimumab

#38 | 2018-02-01

US20180028668A1

Human necessities

Etanercept formulations stabilized with xylitol

#39 | 2018-02-01

US20180028657A1

Human necessities

Stable Aqueous Formulations of Adalimumab

#40 | 2018-02-01

US20180028656A1

Human necessities

Stable Aqueous Formulations of Adalimumab

#41 | 2018-02-01

US20180028655A1

Human necessities

Stable Aqueous Formulations of Adalimumab

#42 | 2018-02-01

US20180028654A1

Human necessities

Methods of manufacturing stable aqueous formulations of adalimumab

#43 | 2018-02-01

US20180028653A1

Human necessities

Syringe containing stable aqueous formulations of adalimumab

#44 | 2018-01-25

US20180021433A1

Human necessities

Stable aqueous formulations of adalimumab

#45 | 2017-11-02

US20170312361A1

Human necessities

Stable aqueous formulations of adalimumab

#46 | 2017-10-26

US20170304445A1

Human necessities

Method of filling a container with no headspace

#47 | 2017-03-16

US20170072054A1

Human necessities

Stable aqueous formulations of adalimumab

#48 | 2016-11-03

US20160317667A1

Human necessities

Etanercept formulations stabilized with xylitol

#49 | 2016-10-20

US20160304601A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#50 | 2016-10-20

US20160304600A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#51 | 2016-10-20

US20160304599A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#52 | 2016-10-20

US20160303235A1

Human necessities

Stable aqueous formulations of adalimumab

#53 | 2016-10-20

US20160303234A1

Human necessities

Stable aqueous formulations of adalimumab

#54 | 2016-10-20

US20160303233A1

Human necessities

Stable aqueous formulations of adalimumab

#55 | 2016-09-15

US20160263226A1

Human necessities

Stable aqueous formulations of adalimumab

#56 | 2016-09-08

US20160256547A1

Human necessities

Stable aqueous formulations of adalimumab

#57 | 2016-09-08

US20160256546A1

Human necessities

Stable aqueous formulations of adalimumab

#58 | 2016-09-08

US20160256545A1

Human necessities

Stable aqueous formulations of adalimumab

#59 | 2016-07-14

US20160199489A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#60 | 2016-02-11

US20160039926A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#61 | 2016-02-04

US20160031982A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#62 | 2015-07-16

US20150196645A1

Human necessities

Stable aqueous formulations of etanercept

#63 | 2015-07-09

US20150191539A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#64 | 2015-07-09

US20150191538A1

Chemistry; metallurgy

Stable aqueous formulations of adalimumab

#65 | 2015-07-09

US20150190513A1

Human necessities

Stable aqueous formulations of adalimumab

#66 | 2015-07-09

US20150190512A1

Human necessities

Stable aqueous formulations of adalimumab

#67 | 2015-07-02

US20150182626A1

Human necessities

Stable aqueous formulations of adalimumab

#68 | 2015-05-07

US20150125532A1

Human necessities

Etanercept formulations exhibiting marked reduction in sub-visible particles

#69 | 2014-07-03

US20140186361A1

Human necessities

Stable Aqueous Formulations of Adalimumab

#70 | 2013-05-23

US20130131192A1

Human necessities

COMPOSITION, METHOD, AND KIT FOR ALPHA-1 PROTEINASE INHIBITOR

#71 | 2013-05-02

US20130108634A1

Human necessities

Etanercept formulations stabilized with meglumine

#72 | 2013-05-02

US20130108633A1

Human necessities

Etanercept formulations stabilized with metal ions

#73 | 2013-05-02

US20130108632A1

Human necessities

Etanercept formulations stabilized with amino acids

#74 | 2013-04-25

US20130101640A1

Human necessities

Etanercept formulations stabilized with combinations of sugars and polyols

#75 | 2013-04-25

US20130101584A1

Human necessities

Etanercept formulations stabilized with xylitol

#76 | 2013-04-25

US20130101583A1

Human necessities

Etanercept formulations stabilized with sodium chloride

InventorID:

209033 ⎘